MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum

The frequent overexpression of CD46 in malignant tumors has provided a basis to use vaccine-lineage measles virus (MeV) as an oncolytic virotherapy platform. However, widespread measles seropositivity limits the systemic deployment of oncolytic MeV for the treatment of metastatic neoplasia. Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Muñoz-Alía, Miguel Ángel, Nace, Rebecca A., Tischer, Alexander, Zhang, Lianwen, Bah, Eugene S., Auton, Matthew, Russell, Stephen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886131/
https://www.ncbi.nlm.nih.gov/pubmed/33534834
http://dx.doi.org/10.1371/journal.ppat.1009283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886131/
https://www.ncbi.nlm.nih.gov/pubmed/33534834
http://dx.doi.org/10.1371/journal.ppat.1009283

Ejemplares similares